Skip to content

A Message To Our Clients

A Message To Our Clients

To Our Clients,


First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service that you have become accustomed to.  If you have any questions regarding our Business Continuation Plan, please reach out to info@arfinnmed.com.


We understand that routines will be temporarily changed in the coming months, so we are adapting to accommodate this change.  This means building out a more robust telemedicine system, increasing our patient portal functionality,  generating consents to be e-signed, and streamlining our patient intake process to cut down on wait times.  


As we settle into new workflows and challenges, we will suspend all monthly fees for using Arfinn Med until June 1st.  We also will activate our full suite of functionality to all current users so you are able to offer the best care to patients in the interim.  We know this doesn’t seem like much in these times, but we want to show our gratitude to the medical professionals who are on the front lines helping patients get the help they desperately need.  If you haven’t already, you will be seeing these updates on your account over the weekend. 


Please stay safe, and let us know if you require anything to continue running your practices.  I have set aside a development team to continually assess how to improve care and keep stakeholders safe.
Sincerely, 


James West CEO

Stories you may be interested in

New study finds cannabis effective for treating migraines

A study published last month in the Journal of Pain found a statistically significant reduction in migraine and headache symptoms and recurrences among patients who used cannabis for treatment.Smoking cannabis reduced the severity and length of migraine episodes by nearly half. Researchers concluded that headache and migraine severity were reduced by nearly 50% after using cannabis. The study, conducted by researchers…
Read More →

DeSantis OKs telehealth for Florida medical marijuana patients

TAMPA, Fla. (WFLA) — Florida Gov. Ron DeSantis signed a bill allowing the state’s 828,000 medical marijuana patients to use telehealth to visit their doctors. On Monday, DeSantis signed HB-387, titled “Medical Use of Marijuana,” which allows patients renewing their medical marijuana recommendation to meet with their doctors online. Currently, patients must visit their doctor in person…
Read More →

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More →

Unstructured EHR data more useful for predictive analytics, study shows

A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More →

Three Key Voices in the Medical Marijuana Industry

As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More →

Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says

Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More →

Leave a Comment

You must be logged in to post a comment.